Aveo Oncology Inc., of Cambridge, Mass., completed a pre-planned futility analysis of its phase III TIVO-3 trial comparing Fotivda (tivozanib) to Nexavar (sorafenib, Bayer AG) in patients with refractory advanced renal cell carcinoma after 128 progression events and decided to continue the trial as planned without modification.